Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could new syphilis tests speed up diagnosis?

NCT ID NCT07089836

Diagnosis Sponsor: American Laboratory Products Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 17, 2026 · Updated 4 times

Summary

This study is testing two new blood test kits designed to diagnose syphilis. Researchers will collect blood samples from 1000 people, including those with symptoms, those at high risk, and healthy controls. The goal is to see how accurate these new kits are compared to standard lab tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ALPCO Syphilis-T and Syphilis-NT CLIA kits (diagnostic devices)
What this could lead to
If successful, these kits could provide a faster, automated way to diagnose syphilis, improving detection and treatment.
What could go wrong
This is a diagnostic accuracy study, not a treatment trial. The kits may not perform as well as expected, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients suspected of syphilis, at high-risk for syphilis, or scheduled for routine syphilis related serological testing will be enrolled in the clinical study.

Ages

13 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male, Female, or Other(s) * Patients undergoing routine syphilis testing (asymptomatic at risk, suspected with symptoms, prior history of syphilis, high risk for syphilis) or previously diagnosed with syphilis through a test performed in an accredited laboratory. * Participants must be willing to provide the required blood samples for the clinical study, in addition to any samples requested by their physician. * Pregnant individuals and children (under 22): 1 clinical study tube of blood. * All other participants (excluding pregnant individuals and children): 2 clinical study tubes of blood. * Participants must be able and willing to sign the informed consent form (ICF). * Participants aged 13 to 17 will be asked to sign an assent form. Written parental or guardian consent will also be required prior to enrollment. The assent form will use age-appropriate language and be reviewed with the participant before any procedures. Exclusion Criteria: * Patients currently being treated with antibiotics or completed a course of antibiotics within the past 30 days * Patients with pre-existing conditions that would make blood collection difficult or harmful * If the samples are not collected in strict accordance with the established sampling protocol, as determined by the study team. * Any medical, psychological, or social condition that, in the judgment of the investigator, could interfere with the participant's ability to comply with study requirements, or pose a risk to their safety, or compromise the integrity of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blooddraw are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV Seropositivity sexually transmitted disease syphilis Treponema infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blooddraw PLASMA SERUM Sexually transmitted infection (STI) Syphilis infection Treponema pallidum Treponema pallidum infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    6 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Chemidox Clinical Trials California

    RECRUITING

    Lancaster, California, 93534, United States

  • Chemidox Tx LLC

    RECRUITING

    Houston, Texas, 77071, United States

  • Folio Clinical Research

    RECRUITING

    Los Angeles, California, 90036, United States

  • IMA Clinical Research - St.Petersburg

    RECRUITING

    St. Petersburg, Florida, 33704, United States

  • Segel Trials

    RECRUITING

    North Miami, Florida, 33161, United States

  • VAST Clinical Research

    RECRUITING

    Mesquite, Texas, 75149, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.